A paper using https://t.co/hCs0MPu0hL (from @LICORBio) was just published in Molecular Cancer Research, see "Mapping of m6A and Its Regulatory Targets in Prost…": https://t.co/aM84LDYVmL (https://t.co/iFTEasjvb8). Thank you for making your #methodsmatter.
Low levels of N6-adenosine-methyltransferase (METTL3) is associated with advanced metastatic #ProstateCancer highlighting the role of N6-methyladenosine. Cotter et al find that METTL3 knockdown rendered the cells resistant to androgen receptor antagonists.
RT @MCR_AACR: Low levels of N6-adenosine-methyltransferase (METTL3) is associated with advanced metastatic #ProstateCancer highlighting the…
Low levels of N6-adenosine-methyltransferase (METTL3) is associated with advanced metastatic #ProstateCancer highlighting the role of N6-methyladenosine. Cotter et al find that METTL3 knockdown rendered the cells resistant to androgen receptor antagonists.
Low levels of N6-adenosine-methyltransferase (METTL3) is associated with advanced metastatic #ProstateCancer highlighting the role of N6-methyladenosine. Cotter et al find that METTL3 knockdown rendered the cells resistant to androgen receptor antagonists.
Low levels of N6-adenosine-methyltransferase (METTL3) is associated with advanced metastatic #ProstateCancer highlighting the role of N6-methyladenosine. Cotter et al find that METTL3 knockdown rendered the cells resistant to androgen receptor antagonists.
RT @MarkARubin1: Mapping of m6A and Its Regulatory Targets in Prostate Cancer Reveals a METTL3-low Induction of Therapy Resistance. Nop Ope…
RT @KellieACotter: Incredibly excited to share the publication of our work on #m6A and #METTL3 in #prostatecancer published as #openaccess…
RT @MarkARubin1: Mapping of m6A and Its Regulatory Targets in Prostate Cancer Reveals a METTL3-low Induction of Therapy Resistance. Nop Ope…
RT @MarkARubin1: Mapping of m6A and Its Regulatory Targets in Prostate Cancer Reveals a METTL3-low Induction of Therapy Resistance. Nop Ope…
RT @MarkARubin1: Mapping of m6A and Its Regulatory Targets in Prostate Cancer Reveals a METTL3-low Induction of Therapy Resistance. Nop Ope…
RT @MarkARubin1: Mapping of m6A and Its Regulatory Targets in Prostate Cancer Reveals a METTL3-low Induction of Therapy Resistance. Nop Ope…
RT @MarkARubin1: Mapping of m6A and Its Regulatory Targets in Prostate Cancer Reveals a METTL3-low Induction of Therapy Resistance. Nop Ope…
RT @KellieACotter: Incredibly excited to share the publication of our work on #m6A and #METTL3 in #prostatecancer published as #openaccess…
RT @MarkARubin1: Mapping of m6A and Its Regulatory Targets in Prostate Cancer Reveals a METTL3-low Induction of Therapy Resistance. Nop Ope…
RT @MarkARubin1: Mapping of m6A and Its Regulatory Targets in Prostate Cancer Reveals a METTL3-low Induction of Therapy Resistance. Nop Ope…
Exciting new work from @KellieACotter and Co!!! @DBMR_UniBe
RT @MarkARubin1: Mapping of m6A and Its Regulatory Targets in Prostate Cancer Reveals a METTL3-low Induction of Therapy Resistance. Nop Ope…
RT @MarkARubin1: Mapping of m6A and Its Regulatory Targets in Prostate Cancer Reveals a METTL3-low Induction of Therapy Resistance. Nop Ope…
RT @KellieACotter: Incredibly excited to share the publication of our work on #m6A and #METTL3 in #prostatecancer published as #openaccess…
Incredibly excited to share the publication of our work on #m6A and #METTL3 in #prostatecancer published as #openaccess in @MCR_AACR. https://t.co/7m1twJyLGR
Mapping of m6A and Its Regulatory Targets in Prostate Cancer Reveals a METTL3-low Induction of Therapy Resistance. Nop Open Access @AACR Congrats to @KellieACotter and Team. @PCF_Science @DBMR_UniBe @NCCR_RNADisease @WCM_PCa_SPORE https://t.co/4yNfrwfLt2
Mapping of m6A and Its Regulatory Targets in #ProstateCancer Reveals a METTL3-low Induction of Therapy Resistance https://t.co/6R0VbJRThU